Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

NCT ID: NCT04002947

This clinical trial is investigating whether a new drug called acalabrutinib can improve treatment outcomes for adults with untreated diffuse large B-cell lymphoma (DLBCL), a common and aggressive ...

Recruiting

Phase: PHASE2 Type: interventional Locations: Bethesda, Maryland, United States

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

NCT ID: NCT05139017

This clinical trial is studying a new treatment called zilovertamab vedotin (ZV) to see how well it works when combined with standard treatments for patients with a type of blood cancer known as re...

Recruiting

Phase: PHASE2 Type: interventional Locations: Wroclaw, Dolnoslaskie, Poland, Warszawa, Mazowieckie, Poland +128 more

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

NCT ID: NCT04512716

The Iomab-ACT trial is a study looking at a new treatment approach for patients with specific types of blood cancers, including relapsed or hard-to-treat B-Cell Acute Lymphoblastic Leukemia (B-ALL)...

Recruiting

Phase: EARLY_PHASE1 Type: interventional Locations: New York, New York, United States, Middletown, New Jersey, United States +5 more

Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET

NCT ID: NCT07070648

This clinical trial is studying a new way to predict how well patients with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) will respond to the usual first treatment. The resear...

Recruiting

Type: observational Locations: Shanghai, Shanghai, China

Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL

NCT ID: NCT04855253

This clinical trial is studying a new treatment approach for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), a type of blood cancer that has not responded to previous tr...

Recruiting

Phase: PHASE1 Type: interventional Locations: Minneapolis, Minnesota, United States

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

NCT ID: NCT06014762

This clinical trial is studying a new treatment called P-CD19CD20-ALLO1, which uses modified immune cells (CAR-T cells) to help fight certain types of blood cancers, specifically different forms of...

Recruiting

Phase: PHASE1 Type: interventional Locations: La Jolla, California, United States, Chapel Hill, North Carolina, United States +10 more

SynKIR-310 for Relapsed/Refractory B-NHL

NCT ID: NCT06544265

The SynKIR-310 trial is a research study aimed at evaluating a new treatment called SynKIR-310 for adults with certain types of B-cell lymphoma that have not responded to previous therapies or have...

Recruiting

Phase: PHASE1 Type: interventional Locations: Fairway, Kansas, United States, Portland, Oregon, United States +1 more

Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients with DLBCL Intolerant to Chemotherapy

NCT ID: NCT06758037

This clinical trial is investigating a new treatment option called HiR+X therapy for elderly patients who have recently been diagnosed with a type of cancer called diffuse large B-cell lymphoma (DL...

Recruiting

Phase: PHASE2 Type: interventional Locations: Ningbo, Zhejiang, China

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

NCT ID: NCT05487170

The CHAMP-1 clinical trial is studying a new treatment called RNK05047 for patients with advanced solid tumors, including a type of blood cancer known as diffuse large B-cell lymphoma (DLBCL). This...

Recruiting

Phase: PHASE1 Type: interventional Locations: Louisville, Kentucky, United States, Atlanta, Georgia, United States +6 more

A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL

NCT ID: NCT06779435

This clinical trial is studying a new treatment called tucidinostat for patients with a type of cancer known as diffuse large B-cell lymphoma (DLBCL). The goal is to see how effective and safe this...

Recruiting

Type: observational Locations: Shanghai, Shanghai, China

Study of Oral MRT-2359 in Selected Cancer Patients

NCT ID: NCT05546268

This clinical trial is studying a new treatment called MRT-2359 for patients with specific types of cancer, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and certain ...

Recruiting

Phase: PHASE1 Type: interventional Locations: New Haven, Connecticut, United States, New York, New York, United States +21 more

A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

NCT ID: NCT03758989

This clinical trial is exploring a new way to treat and monitor patients with a specific type of lymphoma called diffuse large B cell lymphoma (DLBCL). The study aims to measure levels of circulati...

Recruiting

Phase: PHASE2 Type: interventional Locations: Rochester, New York, United States

CR-CHOP+X in Previously Untreated DEL

NCT ID: NCT06701357

This clinical trial, called CR-CHOP+X, is investigating a new treatment approach for patients with a type of cancer known as diffuse large B-cell lymphoma (DLBCL). Specifically, the study is lookin...

Recruiting

Phase: PHASE2 Type: interventional Locations: Shanghai, Shanghai, China

CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p)

NCT ID: NCT06750991

This clinical trial is looking at a new treatment for patients with a type of cancer called diffuse large B-cell lymphoma (DLBCL) who have specific genetic changes known as TP53 mutations and delet...

Not yet recruiting

Phase: PHASE2 Type: interventional Locations: Shanghai, Shanghai, China

A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients with DLBCL

NCT ID: NCT04594798

This clinical trial is looking at a new treatment option for older patients (75 years and older) with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL). The study is testing a com...

Recruiting

Phase: PHASE2 Type: interventional Locations: Rochester, New York, United States

Zanubrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCL

NCT ID: NCT06652165

This clinical trial is studying a new treatment approach for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), a type of blood cancer. Researchers want to see if combining...

Not yet recruiting

Phase: PHASE2 Type: interventional

Study of SGR-1505 in Mature B-Cell Neoplasms

NCT ID: NCT05544019

This clinical trial is studying a new treatment called SGR-1505 for patients with various types of mature B-cell cancers, including Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. The main g...

Recruiting

Phase: PHASE1 Type: interventional Locations: Milwaukee, Wisconsin, United States, Bronx, New York, United States +16 more

A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

NCT ID: NCT04332822

This clinical trial is testing two different treatment plans for elderly patients with a type of cancer called diffuse large B-cell lymphoma (DLBCL), which is a serious form of lymphoma. The study ...

Recruiting

Phase: PHASE3 Type: interventional Locations: Aviano, , Italy, Perth, , Australia +70 more

A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients

NCT ID: NCT06569485

This clinical trial is studying a new treatment approach for patients with Diffuse Large B-Cell Lymphoma (DLBCL), a type of blood cancer. The researchers are looking at the effects of a drug called...

Recruiting

Phase: PHASE2 Type: interventional Locations: Guangzhou, Guangdong, China

Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT ID: NCT06521255

This clinical trial is looking at two different treatment combinations for patients with a type of blood cancer called relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study is com...

Recruiting

Phase: PHASE3 Type: interventional Locations: Beijing, , China, Guangzhou, Guangdong, China +18 more

Main Menu

Clinical Trials for DLBCL

29 Active Trials Found

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET

Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

SynKIR-310 for Relapsed/Refractory B-NHL

Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients with DLBCL Intolerant to Chemotherapy

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL

Study of Oral MRT-2359 in Selected Cancer Patients

A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

CR-CHOP+X in Previously Untreated DEL

CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p)

A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients with DLBCL

Zanubrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCL

Study of SGR-1505 in Mature B-Cell Neoplasms

A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients

Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Related Conditions